15-04-2024 | Acute Coronary Syndrome | Interventional Cardiology (SR Bailey and T Helmy, Section Editors)
Drug-Coated Balloon in Acute Coronary Syndromes: Ready for the Prime Time?
Published in: Current Cardiology Reports
Login to get accessAbstract
Purpose of Review
Acute coronary syndromes (ACS) are a major global health concern. Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) has been endorsed as safe and effective in the management of culprit and non-culprit lesions of ACS. However, permanent metallic implants may have drawbacks, including the need for prolonged dual antiplatelet therapy (DAPT) and the risk of long-term stent-related complications. An alternative approach using drug-coated balloons (DCBs) is gaining growing interest, having the potential of delivering therapy directly to vulnerable plaques, avoiding the need for permanent metallic implants, and potentially allowing for better long-term medical treatment. Despite limited evidence, DCB is being explored in several patients’ subgroups. This review aims to discuss the existing evidence regarding DCB in ACS management.
Recent Findings
DCB appears to be a promising strategy in the management of ACS, showing comparable angiographic and clinical results as compared to new-generation DES in relatively small clinical trials or large prospective registries. The advantage of avoiding permanent implants is particularly appealing in this setting, where DCB has the potential of delivering anti-atherogenic local therapy directly to vulnerable plaques still amenable to atherogenic regression. This review seeks to underline the theoretical background of DCB use and reports the available evidence in its support in the specific setting of ACS.
Summary
In the context of ACS, the use of DCB is highly attractive, offering a dedicated anti-atherogenic local therapy, capable of addressing a broad range of vulnerable plaques and patients.
Graphical Abstract
A snapshot of the entire manuscript demonstrating DCB technology with potential benefits in ACS settings and particularly its role in vulnerable plaques with a scheme defining these vulnerable plaques and identifying the patient population who benefits the most from DCB approach treatment.
×